Gut Microbiota in Irritable Bowel Syndrome and Inflammatory Bowel Disease: Differences in Pathophysiology, Biomarkers, and Treatment Implications.

Pastras P, Aggeletopoulou I, Psalti V, Triantos C

Open source

DOI
10.3390/ph19050783
Published
2026 May 17
Container
Pharmaceuticals (Basel, Switzerland)
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/ph19050783,
  title = {Gut Microbiota in Irritable Bowel Syndrome and Inflammatory Bowel Disease: Differences in Pathophysiology, Biomarkers, and Treatment Implications.},
  author = {Pastras P and Aggeletopoulou I and Psalti V and Triantos C},
  year = {2026},
  journal = {Pharmaceuticals (Basel, Switzerland)},
  doi = {10.3390/ph19050783},
  url = {https://doi.org/10.3390/ph19050783}
}

RIS

TY  - JOUR
TI  - Gut Microbiota in Irritable Bowel Syndrome and Inflammatory Bowel Disease: Differences in Pathophysiology, Biomarkers, and Treatment Implications.
AU  - Pastras P
AU  - Aggeletopoulou I
AU  - Psalti V
AU  - Triantos C
PY  - 2026
JO  - Pharmaceuticals (Basel, Switzerland)
DO  - 10.3390/ph19050783
UR  - https://doi.org/10.3390/ph19050783
ER  - 

APA

P, P., I, A., V, P., & C, T. (2026). Gut Microbiota in Irritable Bowel Syndrome and Inflammatory Bowel Disease: Differences in Pathophysiology, Biomarkers, and Treatment Implications.. Pharmaceuticals (Basel, Switzerland). https://doi.org/10.3390/ph19050783

Source records